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Abstract Background: The six 
dose regimen of Artemether-
Lumefantrine (AL), has high effi-
cacy in clinical trials and is the first
-line drug for treating uncompli-
cated malaria in Nigeria. The com-
plex dosage schedule could militate 
against its effectiveness. 
Objective: To assess the effective-
ness of AL prescribed under rou-
tine outpatient conditions in the 
treatment of uncomplicated ma-
laria.  
Methods: An open label, non-
comparative trial to assess the ef-
fectiveness of AL in children 6 to 
59 months with uncomplicated P. 
falciparum and parasite density 
between 1,000 and 250,000/µL. 
Enrolled children received 6-dose 
course of AL (20/120mg tablets). 
The first dose was administered in 
the health facility and caregivers 
were instructed on how to adminis-
ter the remaining five doses at 
home.  
Results: Of the 1035 screened, 215 
eligible children were enrolled and 
193 completed the study. Twenty-
two (22) patients withdrew from the 
study (18 were lost to follow-up, 3 
violated protocol and 1 withdrew 
consent). Adequate clinical and 
parasitological response (ACPR) 
was observed in 90.7%; late clinical 
failure in 7 (3.6%) and late parasi-
tological failure in 11 (5.7%).  
Conclusion: This study showed 
high efficacy of AL in treating un-
complicated P. falciparum malaria 
in under-fives in Nigeria. Adher-
ence by caregivers to the treatment 
regimen was  quite good and so, 





ence, uncomplicated malaria. 
Introduction 
 
The global burden of malaria is well described1,2 with 
90% of global episodes of clinical malaria and mortality 
occurring in sub-Sahara Africa. The malaria control 
situation became worse following the emergence of anti-
malarial drug resistance and more recently by reports of 
resistance to artemisinin product from South East Asia. 
Early diagnosis and prompt treatment during malaria 
episodes are the key components of the global strategy 
for malaria control.3 
 
In Nigeria, about 50% of the population suffers at least 
one episode of malaria every year and malaria accounts 
for over 45 per cent of all out-patient visits. The disease 
accounts for 25 % infant and 30 % childhood mortality 
in the country. 4 Results of randomized control trials 
conducted in different parts of the world including Nige-
ria,5-8 showed that artemisinin-based combination ther-
apy (ACT) are efficacious and safe . In line with the 
recommendation of world health organization (WHO), 
the Nigerian Federal Ministry of Health changed the
malaria treatment policy in 2005,9 to artemisinin-based 
combination therapy. Artemether-Lumefantrine (AL) 
was the first ACT approved for use as first-line in the 
treatment of uncomplicated falciparum malaria.  
Artemeter-Lumefantrine is co-formulated hence it isless 
likely to be misused as monotherapy unlike the co-
packaged ACTs.8 However, its use as the drug of choice 
in Nigeria can be limited by partial adherence with the 
recommended 6 dose regimen and the interval of 8 hours 
between the first and the second dose, 24 hours between 
the first and the third dose, and 12 hourly intervals be-
tween the remaining doses. The main concern of AL use 
is its timed dosage multi-dose schedule, raising the   
question of whether it will remain effective when used 
on an unsupervised basis in the community.  
The effectiveness of an intervention is the ability to 
achieve the desired aim when used in an unsupervised 
setting and it depends on compliance with the recom-
mended treatment regimen.10 Poor adherence is likely to 
decrease treatment effectiveness and expose the parasite 
to sub-therapeutic drug levels which may favour devel-
opment of resistance to the drug.10 Most clinical trials 
assess the efficacy and safety of drugs under supervised 
settings. The cure rate of a drug reported from clinical 
trial may not be the same as that observed under routine 
out patient conditions. Since there could be differences 
between the efficacy of a drug during clinical trial and 
its effectiveness on routine use, it is important to assess 
the effectiveness of AL, the first line anti-malarial drug 
presently in use in Nigeria.  
 
The aim of this study was to assess the effectiveness of 
AL under routine outpatient conditions in the treatment 





Methods and Patients 
 
Design: This was an open label non-randomized trial to 
determine the effectiveness of AL for treating uncompli-
cated P. falciparum malaria in children aged 6 to 59 
months. 
 
Study Population: The study was conducted over 13 
month period from June 2006 to June 2007. Children 
with features suggestive of uncomplicated malaria, at-
tending the outpatient clinic at a Health Centre in Ikot 
Ansa, Calabar Municipality, South Eastern Nigeria were 
screened for inclusion.   
 
Inclusion criteria: Participants were eligible for inclu-
sion if they were between 6 and 59 months old, had fe-
ver (axillary temperature ≥ 37.5°C) or history of fever in 
the past 24 hours with P. falciparum asexual parasites 
between 1000 and 250,000/µL. In addition, participants 
were resident in the study area to be eligible for enrol-
ment. Finally, a signed informed consent was mandatory 
for inclusion in the study. 
 
Exclusion criteria: Participants were excluded if there 
was known allergy to any of the study drug components, 
vomiting study drug two or more consecutive times; 
packed cell volume <15%, other manifestation of com-
plicated malaria and any other danger sign of childhood 
illness such as severe malnutrition, not able to sit, stand 
or drink, recent history of convulsion, lethargic or un-
consciousness. 
 
The Ethical Review Committee of the University of 
Calabar Teaching Hospital approved the protocol for the 
study.  A written informed consent was obtained from 
each parent/legal guardian of eligible participants prior 
to enrolment. 
 
The intervention: was a co-formulated preparation of 
Artemether (20mg) and Lumefantrine (120mg) in each 
tablet presented in a blister form. The dosing schedule 
requires intervals of 0, 8, 24, 36, 48 and 60 hours, the 
interval between the first two doses are crucial to the 
eventual outcome of treatment. The blister pack contains 
pictures and instructions on how the drug should be ad-
ministered. The dosage is based on the child’s weight. 
The detail of the dosage of AL is shown in Table 1.  
 
Table 1: Dosage schedule of artemether-lumefantrine 
Drug administration: Once a participant was enrolled, 
the first dose of AL was administered to the patient in 
the health facility under the supervision of the study 
nurse. The child was then observed for 30 minutes in the 
health facility. If the child vomited within this period, 
another dose was given and the participant observed for 
another 30 minutes. A child that vomited two or more 
times within one hour of commencement of drug ad-
ministration was classified as repeated vomiting and 
withdrawn from the study. Such participant was referr d 
to the next level of care for treatment with parenteral 
antimalarial. Those that tolerated the first dose were sent 
home with further instructions on how to administer the 
remaining doses. Emphasis was laid on the importance 
of giving the second dose eight hours after the first dose, 
then two doses per day in the morning and evening for 
the following two days. Parents/guardians were also 
informed that the drug is best given with fatty foods or 
shortly after breastfeeding for children that were still 
breastfeeding.  
 
Clinical Assessments: Clinical assessments include 
history of illness, measurement of axillary temperature 
and weight of participants on day 0 and during follow up 
visits on days 7, 14 and 28. Patients were not reviewed 
on Days 1, 2 and 3 so as not to induce adherence to the 
drug. Guardians/parents were advised to bring back the 
participant to the health facility if the health condition 
deteriorated. Participants that were not brought on 
schedule for follow-up visits were visited at home th  
same day and where that was not possible within two 
days after the scheduled visit date. Rescue medication 
for this study was quinine in line with the Nigerian na-
tional malaria treatment guidelines. 
 
Laboratory investigation: Thick and thin blood film 
specimens were used to screen for presence of malaria 
parasites. During each visit, blood smears were col-
lected, prepared and stained in 3% Giemsa solution for 
30 minutes. Smears were read to 100 fields with quanti 
  Number of tablets/recommended time of administration 
  Day 0 Day 1 Day 2 














  5 – 15 1 1 1 1 1 1 
  15 – 25 2 2 2 2 2 2 
  25 – 35 3 3 3 3 3 3 
   > 35 4 4 4 4 4 4 
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quantification of P. falciparum asexual parasites on the 
thick smear (per uL) and gametocytes (number per 1000 
white cell count). Parasites were enumerated using thick
film as described by Shute.11 Parasite density was calcu-
lated, assuming a normal leucocyte level of 8,000/µl. 
The thin film was used to speciate the parasites.  Packed 
cell volume was determined on days 0, 14 and 28 with
sample collected in a heparinized capillary tube and cen-
trifuged for 5 minutes at 10,000 G. 
 
Withdrawals: Participants who were lost to follow up 
or those that withdrew consent were classified as with-
drawals from the study. Also, participants who took 
other anti-malarial drugs during this period were with-
drawn from the study. All withdrawals were followed up 
for safety except those that were lost to follow up.  
 
Outcome measures: Therapeutic efficacy was assessed 
on follow up visits using WHO guidelines for assessing 
therapeutic efficacy in intense transmission areas.12 
Primary outcome measures were  
 
• Day 28 cure rate: adequate clinical and parasitologi-
cal cure rate (ACPR) 
• Treatment failures which could be  
1. Early treatment failure (ETF) 
2. Late clinical failure (LCF)  
3. Late parasitological failure (LPF)  
• Adherence to recommended treatment schedule. 
 
Secondary outcome measure was safety and tolerability. 
Safety and tolerability was evaluated by the risk of  
occurrence of an adverse event (AE), classified as mild, 
moderate, severe or serious. A serious adverse event was 
defined as any AE resulting in death or in persistent or 
significant disability/incapacity, life-threatening, requir-
ing hospitalization or significant medical interventio  to 
prevent serious outcome. Presence of adverse events 
was assessed based on the assessment given by the 
mother or guardian. 
 









Absence of parasitaemia on Day 28 irrespective of 
axillary temperature without previously meeting any 
of the criteria of Early Treatment Failure, Late  
Clinical Failure and Late Parasitological Failure 
Early treatment 
failure (ETF) 
Development of danger signs or severe malaria on 
Days 1, 2 or 3 in the presence of parasitaemia, or 
parasitaemia on Day 2 higher than Day 0 count 
irrespective of axillary temperature, or parasitaemia 
on Day 3 with axillary temperature ≥ 37.5oC, or 
parasitaemia on Day 3 > 25%of Day 0 count irre-
spective of axillary temperature. 
Late clinical 
failure (LCF) 
Development of danger signs or severe malaria and /
or axillary temperature ≥ 37.5oC on any day from 
Day 4 to Day 28 in the presence of parasitaemia 
without previously meeting any of the criteria for 




The presence of parasitaemia from Day 4 to Day 28 
and axillary temperature < 37.5oC without previ-
ously meeting any of the criteria for Early Treatment 
Failure or Late Clinical Failure 
Analysis: Endpoints were assessed based on intention to 
treat analysis. Data generated were recorded in a log 
book and individual patient’s case record files and later 
double - entered into EPI-Info version 3.5.1 software. 







One thousand and thirty five children were screened for 
eligibility, of whom 215 (20.7%) were enrolled. Base-
line characteristics are shown in Table 3.  
 
Table 3: Baseline Characteristics of patients 
Enrolment and follow-up: Figure 1 shows the patient 
flow from screening, treatment, follow-up to comple-
tion. Four hundred and ten (50%) of the 820 excluded 
patients were due to use of anti-malarial drug within wo 
weeks of screening. There were 22 withdrawals in ths 
study as follows; 18 were lost to follow up (traveled out 
of study area), 3 violated protocol (took anti-malari ls 
outside study drug) and one withdrew consent. A total f 
193 (89%) participants completed the study and had 
adequate data for analysis of the study outcomes.  
 
Fig 1: Patient flow diagram for the study 
 
                      Trial Flow Diagram 
                    




Not meeting inclusion criteria: 
•Anti-malarial within 2 weeks = 410  




Allocated to intervention (n = 215) 
• Received allocated intervention (n= 214) 
• Did not receive allocated intervention  
    (incomplete treatment dose) (n=1) 
 
 
Lost to follow-up (travelled out of area) = 18 




Analysed (n= 193) 
• Excluded from analysis (had other anti-malarial      
 drug during follow-up) (n=3) 
Characteristics Mean (SD) N=215 
Age in years(mean ± SD) 2.50±1.70 
Males (%) 123 (57.2) 
Females (%) 92 (42.8) 
Height in cm (Mean ± SD) 91.7 (13.2) 
Weight in Kg (Mean ± SD) 12.7 (3.2) 
Axillary Temperature (Mean ± SD)ºC 37.6 (1.14) 
Packed Cell Volume Day 0 28.0 (4.9) 
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Treatment outcome: Table 4 shows the results of the 
28-day therapeutic efficacy of AL. The number of evalu-
able participants with adequate clinical and parasitologi-
cal response (ACPR) was 175 (90.7%). Late clinical 
failure (LCF) was observed in 5 participants. There were 
11 late parasitological failures; 2 on Day 14, 2 on Day 
25 and 7 on Day 28. 
 
Assessment of patient adherence to treatment: Out of 
the 215 enrolled participants empty blisters were re-
turned for 210 suggesting that most of the participants 
(97.6%) adhered to the recommended dosage schedule. 
Caregivers were interviewed to ascertain how and when 
drugs were given to child. Four caregivers reported that 
they had misplaced the empty blisters hence did not re-
turn them.  One parent did not return the blister because 
the child improved so she reserved the last 2 doses (5th 
and 6th dose) for next episode of malaria attack. 
 
Table 4: Effectiveness of unsupervised artemether-
lumefantrine 
*PCR confirmation not used. 
 
Adverse Events:  There were 48 mild adverse events 
during the study; the most common were cough (7.0%) 
and vomiting study drug at least once (7.0%). Others 
were catarrh (2.3%), headache (2.3%), abdominal pain
(1.3%) and rashes (1%). No serious adverse event was 
observed in any of the study participants.  
 
Change in Haemoglobin: The packed cell volume in-
creased in all participants by the end of the follow up 
period. The mean haematocrit value increased from 28%






This study has shown that Artemeter-Lumefantrine is 
effective with a cure rate of 90.7% when administered in 
unsupervised setting. Reports from a multicentre study 
on the effectiveness of home management of malaria in 
which Nigeria was one of the study sites gave a PCR-
corrected cure rate of 90.9%,13 The cure rate of this 
study though uncorrected for reinfection is similar to the 
PCR –corrected cure rate of the multi-centre study. In a 
randomized trial of effectiveness of AL in Ghana, 
Kobbe et al14 reported parasitological cure rate of 88.3% 
for AL, which is similar to the findings of this study. 
However, in a report from Uganda, higher cure rate of 
98.0% was observed when AL was given in unsuper-
vised setting.15 It therefore appears that the drug has 






Day-28 cure (Adequate clinical and 
parasitological response - ACPR)* 175 90.7% 
Late clinical failure (LCF) 7 3.6% 
Late parasitological failure (LPF) 11 5.7% 
In this study, 97.6% of the caregivers adhered to the 
dosage recommendation. Since the effectiveness of any 
drug combination therapy is dependent on adherence 
with the treatment regimen,10 it is assumed that the effi-
cacy reported in this study is as a result of acceptable 
compliance with the treatment regimen. It therefore ap-
pears that majority of caregivers in this locality adhere 
to the 6 doses of AL although it is difficult to say 
whether they observe the 8 hours interval between th  
first and the second doses. In the study by Ajayi et al13, 
average adherence for the 3 countries that participa ed in 
the study was 94%. However, Depoortere et al16 in 
southern Sudan reported that 18.3% of the participants 
were ‘not adherent’ to the dosage schedule. However, in 
their study emphasis was placed on giving the drug with 
milk or fatty foods and some of the caregivers did not
administer the drug because of lack of milk or fatty food 
to precede the drug. In this study, emphasis was not 
placed on giving drug with milk or fatty food because an 
earlier efficacy test in the same centre did not lay em-
phasis on the dietary component and the cure rate ob-
tained in this study is similar to that of the previous 
study.8 
 
Several factors may have contributed to the high adher-
ence observed in this study. Firstly, the fact thatcaregiv-
ers were required to return the empty blisters on day 7 
may have played an indirect role in enhancing adher-
ence. Secondly, the packaging of the drug might also
have promoted adherence. The sealed-blister design 
contains visual depictions of time intervals and number 
of tablets to be taken by the patients.16,17 However, the 
packaging is universal and available to non-study par-
ents, hence it is considered an important aid by the 
manufacturers to promote adherence. Also the added 
verbal explanation by the team members to caregivers 
have been shown to improve adherence.17  
 
AL was well-tolerated with no serious adverse events 
and only few mild adverse events in this study furthe  
confirms the safety of the combination. This has been 
documented by other studies.8,18 
 
The limitations of this study include the non-randomized 
design, and the absence of a comparator. Also, the small 
sample size of the study makes generalization difficult. 
On the other hand, polymerase chain reaction was not 
used to differentiate actual parasitological failures 
(recrudescence) from new infections hence day-28 cure
rate could have been higher than reported. Finally, the 
adherence observed in this semi-urban setting cannot be 






Despite the complexity of the 6 dose AL regimen, the 
high day 28 parasitological cure in this and other studies 
shows that the drug is effective when used in unsuper-
vised outpatient settings in Nigeria, even among care-
givers with low level of education. It is important for  
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healthcare providers to give sufficient explanation on the 
correct method of administering drugs to caregivers. We 
recommend multicentre, randomized trials with larger 
sample sizes across the country to confirm the effectiv -
ness of artemether-lumefantrine as this is essential to 
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